ID
16622
Beschreibung
Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc ( OSI Pharmaceuticals ) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Screening Assessments
Link
https://clinicaltrials.gov/ct2/show/NCT00373425
Stichworte
Versionen (2)
- 27.07.16 27.07.16 -
- 01.08.16 01.08.16 -
Hochgeladen am
27. Juli 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 3.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors (RADIANT) NCT00373425
Test Screening Assessments NCT00373425
- StudyEvent: ODM
Beschreibung
Demographics
Beschreibung
Date of birth
Datentyp
date
Alias
- UMLS CUI [1]
- C0421451
Beschreibung
Gender
Datentyp
integer
Alias
- UMLS CUI [1]
- C0079399
Beschreibung
Ethnicity
Datentyp
integer
Alias
- UMLS CUI [1]
- C0015031
Beschreibung
Race
Datentyp
integer
Alias
- UMLS CUI [1]
- C0034510
Beschreibung
Race
Datentyp
text
Alias
- UMLS CUI [1]
- C0034510
Beschreibung
Screening Eligibility Criteria
Beschreibung
Inclusion Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1512693
Beschreibung
Inclusion Criteria
Datentyp
text
Alias
- UMLS CUI [1]
- C1512693
Beschreibung
Exclusion Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0680251
Beschreibung
Exclusion Criteria
Datentyp
text
Alias
- UMLS CUI [1]
- C0680251
Beschreibung
Eligibility Criteria
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348482
Beschreibung
Date screening consent was signed
Datentyp
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0021430
Beschreibung
IVRS Screening Number
Datentyp
text
Alias
- UMLS CUI [1]
- C1710477
Beschreibung
Treatment Eligibility Criteria
Beschreibung
Inclusion Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C1512693
Beschreibung
Inclusion Criteria
Datentyp
text
Alias
- UMLS CUI [1]
- C1512693
Beschreibung
Exclusion Criteria
Datentyp
boolean
Alias
- UMLS CUI [1]
- C0680251
Beschreibung
Exclusion Criteria
Datentyp
text
Alias
- UMLS CUI [1]
- C0680251
Beschreibung
Eligibility Criteria
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348482
Beschreibung
Date main study consent was signed
Datentyp
date
Alias
- UMLS CUI [1,1]
- C0011008
- UMLS CUI [1,2]
- C0021430
Beschreibung
IVRS Randomization
Ähnliche Modelle
Test Screening Assessments NCT00373425
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,2])
C2348482 (UMLS CUI [1,2])
C0021430 (UMLS CUI [1,2])
C0034656 (UMLS CUI [1,2])